NeuroVive Pharmaceutical AB, a leader in mitochondrial medicine, and Yungjin Pharm Corporation Ltd have jointly announced that they have entered into a global licensing agreement on Yungjin Pharm’s compound KL1333 for genetic mitochondrial disorders. The in-licensed project is about to enter phase I clinical development.